Baidu
map

Genetics:Pla2g2a基因变异影响结肠癌的形成

2014-09-28 佚名 生物谷

由Kristi Neufeld博士领导的科学研究新发现,可能对癌症实验研究以及研究人员如何在小鼠体内测试抗癌药物、并最终对预防结肠癌产生潜在的重要影响。 Neufeld博士重点研究了一种可以防止结肠癌的基因——结肠腺瘤性息肉病基因(adenomatous polyposis coli,APC)。她的许多实验涉及到利用APC基因突变(这会导致结肠癌)小鼠来测试,观察是否会有针对该突变的新化合物。

由Kristi Neufeld博士领导的科学研究新发现,可能对癌症实验研究以及研究人员如何在小鼠体内测试抗癌药物、并最终对预防结肠癌产生潜在的重要影响。

Neufeld博士重点研究了一种可以防止结肠癌的基因——结肠腺瘤性息肉病基因(adenomatous polyposis coli,APC)。她的许多实验涉及到利用APC基因突变(这会导致结肠癌)小鼠来测试,观察是否会有针对该突变的新化合物。

几年前,Neufeld博士的研究小组发现,某些APC基因突变小鼠不会像其他APC基因突变鼠一样,发展患上结肠肿瘤。由于未患上结肠肿瘤的APC基因突变小鼠数量有限,因此未能利用其进行药物测试,Maged Zeineldin博士表示:由于不想让研究就此停止,他们继续探讨了结肠肿瘤发生频率意外减少的原因,并将报告发表在Genetics杂志上。

Neufeld博士的实验室发现了为什么有些APC基因突变小鼠发生有较少的肿瘤,研究发现这些小鼠Pla2g2a有基因修饰(基因变化),保护它们避免患上肿瘤。他们怀疑远交系无胸腺裸鼠(其通常用于抗肿瘤药物测试)也有Pla2g2a改变,后者可影响肿瘤的生长。

Neufeld博士说:我们想也许Pla2g2a变化可能会影响到其他致瘤性的研究。如果你将人类结肠癌细胞注入裸鼠体内,你不知道Pla2g2a改变的存在与否,因此也就不知道Pla2g2a改变会不会影响动物实验结果。

Neufeld博士现在将筛选老鼠Pla2g2a的多态性,并希望在此基础上进行其他癌症的研究,尤其是测试新的药物治疗,并弄清楚Pla2g2a遗传修饰如何改变实验的结果。

她解释说:我们认为这是非常重要的,因为如果有人注射癌细胞到裸鼠体内,裸鼠体内会生长肿瘤,然后给予一种化合物,看该化合物如何治疗癌症,但你不知道你看到的该化合物抗肿瘤结果是由于测试化合物真正有抗肿瘤效果,还是远交裸鼠基因差异所导致的。

Neufeld博士希望与其他实验室合作以确定是否Pla2g2a基因修饰会在人体产生类似的效果,以及Pla2g2a的过度表达是否可以预防人类结肠癌形成。这项新的研究发现有助于预防癌症或筛选出可能预测一个人患结肠癌风险的基因变异。也许医生有一天会像筛选BRCA或HER2基因一样,筛选Pla2g2a的变化,但研究人员首先必须弄明白Pla2g2a改变是否有助于防止肿瘤。

原始出处

Zeineldin M1, Jensen D2, Paranjape SR2, Parelkar NK3, Jokar I3, Vielhauer GA3, Neufeld KL4.Human Cancer Xenografts in Outbred Nude Mice Can Be Confounded by Polymorphisms in a Modifier of Tumorigenesis.Genetics. 2014 Jun 9

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1733714, encodeId=77971e33714d8, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sun Jun 14 06:09:00 CST 2015, time=2015-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877946, encodeId=06eb18e7946c5, content=<a href='/topic/show?id=5d80e943ef' target=_blank style='color:#2F92EE;'>#Genetics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7943, encryptionId=5d80e943ef, topicName=Genetics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Mon Nov 03 01:09:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685968, encodeId=fc911685968da, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Thu Aug 27 07:09:00 CST 2015, time=2015-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048618, encodeId=63de20486185f, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Jan 07 18:09:00 CST 2015, time=2015-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789102, encodeId=2ecc1e8910234, content=<a href='/topic/show?id=34871434005' target=_blank style='color:#2F92EE;'>#PLA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14340, encryptionId=34871434005, topicName=PLA2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2b4297, createdName=徐岩, createdTime=Thu May 28 18:09:00 CST 2015, time=2015-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314132, encodeId=235b1314132da, content=<a href='/topic/show?id=b5e641e1279' target=_blank style='color:#2F92EE;'>#基因变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41712, encryptionId=b5e641e1279, topicName=基因变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Tue Sep 30 00:09:00 CST 2014, time=2014-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342308, encodeId=8db11342308f8, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Tue Sep 30 00:09:00 CST 2014, time=2014-09-30, status=1, ipAttribution=)]
    2015-06-14 canlab
  2. [GetPortalCommentsPageByObjectIdResponse(id=1733714, encodeId=77971e33714d8, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sun Jun 14 06:09:00 CST 2015, time=2015-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877946, encodeId=06eb18e7946c5, content=<a href='/topic/show?id=5d80e943ef' target=_blank style='color:#2F92EE;'>#Genetics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7943, encryptionId=5d80e943ef, topicName=Genetics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Mon Nov 03 01:09:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685968, encodeId=fc911685968da, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Thu Aug 27 07:09:00 CST 2015, time=2015-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048618, encodeId=63de20486185f, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Jan 07 18:09:00 CST 2015, time=2015-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789102, encodeId=2ecc1e8910234, content=<a href='/topic/show?id=34871434005' target=_blank style='color:#2F92EE;'>#PLA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14340, encryptionId=34871434005, topicName=PLA2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2b4297, createdName=徐岩, createdTime=Thu May 28 18:09:00 CST 2015, time=2015-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314132, encodeId=235b1314132da, content=<a href='/topic/show?id=b5e641e1279' target=_blank style='color:#2F92EE;'>#基因变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41712, encryptionId=b5e641e1279, topicName=基因变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Tue Sep 30 00:09:00 CST 2014, time=2014-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342308, encodeId=8db11342308f8, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Tue Sep 30 00:09:00 CST 2014, time=2014-09-30, status=1, ipAttribution=)]
    2014-11-03 huperzia
  3. [GetPortalCommentsPageByObjectIdResponse(id=1733714, encodeId=77971e33714d8, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sun Jun 14 06:09:00 CST 2015, time=2015-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877946, encodeId=06eb18e7946c5, content=<a href='/topic/show?id=5d80e943ef' target=_blank style='color:#2F92EE;'>#Genetics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7943, encryptionId=5d80e943ef, topicName=Genetics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Mon Nov 03 01:09:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685968, encodeId=fc911685968da, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Thu Aug 27 07:09:00 CST 2015, time=2015-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048618, encodeId=63de20486185f, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Jan 07 18:09:00 CST 2015, time=2015-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789102, encodeId=2ecc1e8910234, content=<a href='/topic/show?id=34871434005' target=_blank style='color:#2F92EE;'>#PLA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14340, encryptionId=34871434005, topicName=PLA2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2b4297, createdName=徐岩, createdTime=Thu May 28 18:09:00 CST 2015, time=2015-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314132, encodeId=235b1314132da, content=<a href='/topic/show?id=b5e641e1279' target=_blank style='color:#2F92EE;'>#基因变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41712, encryptionId=b5e641e1279, topicName=基因变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Tue Sep 30 00:09:00 CST 2014, time=2014-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342308, encodeId=8db11342308f8, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Tue Sep 30 00:09:00 CST 2014, time=2014-09-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1733714, encodeId=77971e33714d8, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sun Jun 14 06:09:00 CST 2015, time=2015-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877946, encodeId=06eb18e7946c5, content=<a href='/topic/show?id=5d80e943ef' target=_blank style='color:#2F92EE;'>#Genetics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7943, encryptionId=5d80e943ef, topicName=Genetics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Mon Nov 03 01:09:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685968, encodeId=fc911685968da, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Thu Aug 27 07:09:00 CST 2015, time=2015-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048618, encodeId=63de20486185f, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Jan 07 18:09:00 CST 2015, time=2015-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789102, encodeId=2ecc1e8910234, content=<a href='/topic/show?id=34871434005' target=_blank style='color:#2F92EE;'>#PLA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14340, encryptionId=34871434005, topicName=PLA2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2b4297, createdName=徐岩, createdTime=Thu May 28 18:09:00 CST 2015, time=2015-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314132, encodeId=235b1314132da, content=<a href='/topic/show?id=b5e641e1279' target=_blank style='color:#2F92EE;'>#基因变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41712, encryptionId=b5e641e1279, topicName=基因变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Tue Sep 30 00:09:00 CST 2014, time=2014-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342308, encodeId=8db11342308f8, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Tue Sep 30 00:09:00 CST 2014, time=2014-09-30, status=1, ipAttribution=)]
    2015-01-07 cy0324
  5. [GetPortalCommentsPageByObjectIdResponse(id=1733714, encodeId=77971e33714d8, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sun Jun 14 06:09:00 CST 2015, time=2015-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877946, encodeId=06eb18e7946c5, content=<a href='/topic/show?id=5d80e943ef' target=_blank style='color:#2F92EE;'>#Genetics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7943, encryptionId=5d80e943ef, topicName=Genetics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Mon Nov 03 01:09:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685968, encodeId=fc911685968da, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Thu Aug 27 07:09:00 CST 2015, time=2015-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048618, encodeId=63de20486185f, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Jan 07 18:09:00 CST 2015, time=2015-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789102, encodeId=2ecc1e8910234, content=<a href='/topic/show?id=34871434005' target=_blank style='color:#2F92EE;'>#PLA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14340, encryptionId=34871434005, topicName=PLA2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2b4297, createdName=徐岩, createdTime=Thu May 28 18:09:00 CST 2015, time=2015-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314132, encodeId=235b1314132da, content=<a href='/topic/show?id=b5e641e1279' target=_blank style='color:#2F92EE;'>#基因变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41712, encryptionId=b5e641e1279, topicName=基因变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Tue Sep 30 00:09:00 CST 2014, time=2014-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342308, encodeId=8db11342308f8, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Tue Sep 30 00:09:00 CST 2014, time=2014-09-30, status=1, ipAttribution=)]
    2015-05-28 徐岩
  6. [GetPortalCommentsPageByObjectIdResponse(id=1733714, encodeId=77971e33714d8, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sun Jun 14 06:09:00 CST 2015, time=2015-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877946, encodeId=06eb18e7946c5, content=<a href='/topic/show?id=5d80e943ef' target=_blank style='color:#2F92EE;'>#Genetics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7943, encryptionId=5d80e943ef, topicName=Genetics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Mon Nov 03 01:09:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685968, encodeId=fc911685968da, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Thu Aug 27 07:09:00 CST 2015, time=2015-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048618, encodeId=63de20486185f, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Jan 07 18:09:00 CST 2015, time=2015-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789102, encodeId=2ecc1e8910234, content=<a href='/topic/show?id=34871434005' target=_blank style='color:#2F92EE;'>#PLA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14340, encryptionId=34871434005, topicName=PLA2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2b4297, createdName=徐岩, createdTime=Thu May 28 18:09:00 CST 2015, time=2015-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314132, encodeId=235b1314132da, content=<a href='/topic/show?id=b5e641e1279' target=_blank style='color:#2F92EE;'>#基因变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41712, encryptionId=b5e641e1279, topicName=基因变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Tue Sep 30 00:09:00 CST 2014, time=2014-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342308, encodeId=8db11342308f8, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Tue Sep 30 00:09:00 CST 2014, time=2014-09-30, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1733714, encodeId=77971e33714d8, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sun Jun 14 06:09:00 CST 2015, time=2015-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877946, encodeId=06eb18e7946c5, content=<a href='/topic/show?id=5d80e943ef' target=_blank style='color:#2F92EE;'>#Genetics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7943, encryptionId=5d80e943ef, topicName=Genetics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Mon Nov 03 01:09:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685968, encodeId=fc911685968da, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Thu Aug 27 07:09:00 CST 2015, time=2015-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048618, encodeId=63de20486185f, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Jan 07 18:09:00 CST 2015, time=2015-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789102, encodeId=2ecc1e8910234, content=<a href='/topic/show?id=34871434005' target=_blank style='color:#2F92EE;'>#PLA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14340, encryptionId=34871434005, topicName=PLA2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2b4297, createdName=徐岩, createdTime=Thu May 28 18:09:00 CST 2015, time=2015-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314132, encodeId=235b1314132da, content=<a href='/topic/show?id=b5e641e1279' target=_blank style='color:#2F92EE;'>#基因变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41712, encryptionId=b5e641e1279, topicName=基因变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Tue Sep 30 00:09:00 CST 2014, time=2014-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342308, encodeId=8db11342308f8, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Tue Sep 30 00:09:00 CST 2014, time=2014-09-30, status=1, ipAttribution=)]

相关资讯

CSCO 2014:结肠腺瘤及早期结肠癌的内镜治疗

大肠癌的早期诊断及治疗专场 (1楼1F-2会议室) 报告者:复旦大学附属中山医院 姚礼庆 时间:9 月 18 日 09:30~09:50 内镜黏膜下剥离术(ESD)与内镜黏膜切除术(EMR) 是消化内镜的两种术式,两者均有侵袭小、术后疼痛轻 微、康复快等特点,可用于早期胃肠道肿瘤的微创治疗。 EMR 一般不适用于病灶大于 20 mm 的病变。ESD 对于 较大病灶可以完全整块剥离,且复发率低,

Nat Chem:新型技术可在数分钟内产生自组装的抗癌分子

近日,来自英国华威大学的研究人员通过研究开发了一种简单多用途的方法,该方法可以制造一种人工的抗癌分子,来模拟机体天然防御系统的特性,这种抗癌分子的结构类似于机体的多肽结构,可以帮助机体抵御癌症和感染,相关研究刊登于国际杂志Nature Chemistry上。 研究者表示,目前正在实验室测试中证实这种人工抗癌分子可以有效抑制结肠癌;此前研究人员多肽类分子很难大量生产,但是本文中研究人员开发的

EJCP:酗酒或增结肠癌患者死亡风险

国际癌症研究机构(IARC)最新统计报告显示,饮酒与结直肠癌发生存在一定的因果关系。然而,目前仍不清楚饮酒量与结直肠癌死亡风险之间的具体量化关系。 浙江大学公共卫生学院的 Cai S 团队开展了一项基于流行病学研究的系统性综述和荟萃分析,旨在对不同饮酒量下的结直肠癌死亡风险进行量化分析。该文章于 2014 年 8 月 28 日在线发表在 European Journal of Cancer Pr

JCO:他汀类药物可能有助改善结肠癌患者生存

根据一项英国科学家完成的研究证实:他汀类药物(广泛使用的降胆固醇药物),也可提高结直肠癌患者的存活率。早期研究发现:总体而言,相比非使用者,服用他汀类药物如立普妥的结肠癌患者,死于癌症的风险低29%。服用药物超过一年的患者风险甚至减少更多。这些都是观察性研究,还需要进一步研究确认这些初步的研究结果。在确认之后,一项随机试验(病人不知道他们得到是药物还是安慰剂)是必要的,只有在随机对照试验后,才可以

TAS-102能提高转移性结肠癌患者的存活率

第三期临床试验表明,TAS-102能提高全面提高结肠癌患者的存活率,这些患者的结肠癌已经转移,用普通治疗方法难以治疗。 TAS-102是一种新型的抗癌的核苷类药物,它含有三氟胸苷(trifluridine, FTD)和地匹福林盐酸盐(tipiracil hydrochloride, TPI)。其中,三氟胸苷是TAS-102的活性组成部分,能够直接和癌症的DNA互相作用,使得DNA不能正常行使功能

Baidu
map
Baidu
map
Baidu
map